BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Iovance Biotherapeutics readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Iovance Biotherapeutics's drugs r
 un\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05361174-2555@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:IOV-4001: Phase 1/2 readout est. (NCT05361174)
DESCRIPTION:IOV-4001\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in A
 dult Participants With Unresectable or Metastatic Melanoma or Stage III or
  IV Non-small-cell Lung Cancer\nEstimated primary completion: September 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/iov-4001#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05361174
URL:https://assetmemo.bio/drug/iov-4001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07288203-10883@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Amtagvi (lifileucel): Phase 2 readout est. (NCT07288203)
DESCRIPTION:Amtagvi (lifileucel)\, phase 2\, Melanoma.\nStudy: A Study of L
 ifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanom
 a\nEstimated primary completion: December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/lifileucel#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07288203
URL:https://assetmemo.bio/drug/lifileucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05727904-10883@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Amtagvi (lifileucel): Phase 3 readout est. (NCT05727904)
DESCRIPTION:Amtagvi (lifileucel)\, phase 3\, Melanoma.\nStudy: Study to Inv
 estigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab
  Alone in Participants With Untreated Advanced Melanoma.\nEstimated primar
 y completion: 1 March 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/lifileucel#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT05727904
URL:https://assetmemo.bio/drug/lifileucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06481592-10883@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Amtagvi (lifileucel): Phase 2 readout est. (NCT06481592)
DESCRIPTION:Amtagvi (lifileucel)\, phase 2.\nStudy: A Study of Lifileucel (
 Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer
 .\nEstimated primary completion: May 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/lifileucel#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06481592
URL:https://assetmemo.bio/drug/lifileucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04614103-2048@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:LN-145: Phase 2 readout est. (NCT04614103)
DESCRIPTION:LN-145\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Autologo
 us LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer\nEstimate
 d primary completion: December 2030. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/ln-145#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT04614103
URL:https://assetmemo.bio/drug/ln-145#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06940739-10883@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20320630
DTEND;VALUE=DATE:20320701
SUMMARY:Amtagvi (lifileucel): Phase 1/2 readout est. (NCT06940739)
DESCRIPTION:Amtagvi (lifileucel)\, phase 1/2\, Melanoma.\nStudy: A Study to
  Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced M
 elanoma Who Will Receive Lifileucel\nEstimated primary completion: June 20
 32. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/lifileucel#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06940739
URL:https://assetmemo.bio/drug/lifileucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07741877-10883@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20330901
DTEND;VALUE=DATE:20330902
SUMMARY:Amtagvi (lifileucel): Phase 2 readout est. (NCT07741877)
DESCRIPTION:Amtagvi (lifileucel)\, phase 2.\nStudy: A Study of Lifileucel (
 Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue Sarcom
 a\nEstimated primary completion: 1 September 2033. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/lifileucel#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07741877
URL:https://assetmemo.bio/drug/lifileucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
